Skip to main content
SpringerLink
Log in

Pharmacology of Autism Spectrum Disorder

  • Chapter
  • First Online:
The Molecular Basis of Autism

Part of the book series: Contemporary Clinical Neuroscience ((CCNE))

Abstract

ASD is a complex and common neurobehavioral disorder with no identified single specific biologic etiology. Instead there appear to be diverse abnormalities of brain networks with cellular, biochemical, and genetic factors. Though behavioral therapy is a major component to management of individuals with ASD, psychopharmacology has emerged as an important therapeutic tool. Pharmacology is targeted at associated disorders such as sleep disorders, aggression, anxiety, depression, repetitive behaviors, and hyperactivity. This chapter reviews current agents noted by research trials to be of benefit. Additional medications under current research are also briefly noted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Washington, DC

    Book  Google Scholar 

  • Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, Hollander E (2012) Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 3:6–21

    Article  Google Scholar 

  • Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH (1984) Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195–1202

    Article  CAS  PubMed  Google Scholar 

  • Anderson IM, Kaczmarska J, McGrew S (2008) Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 23:482–485

    Article  Google Scholar 

  • Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y (2006) Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:196–205

    Google Scholar 

  • Antshel KM, Zhang-James Y, Faraone SV (2013) The comorbidity of ADHD and autism spectrum disorder. Expert Rev Neurother 13:1117–1128

    Article  CAS  PubMed  Google Scholar 

  • Bullock TH, Bennett MVL, Johnston D, Josephson R, Marder E, Fields RD (2005) The neuron doctrine, redux. Science 310:791–793

    Article  CAS  PubMed  Google Scholar 

  • Butler MG, Youngs EL, Roberts JL, Hellings JA (2012) Assessment and treatment in autism spectrum disorders: a focus on genetics and psychiatry. Autism Res Treat 2012:1–11

    Article  Google Scholar 

  • Bruni OMS (2007) Sleep in children with autism spectrum disorder. Sleep Med 9:64–70

    Article  PubMed  Google Scholar 

  • Caccia S (2013) Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs 15:217–233

    Article  PubMed  Google Scholar 

  • Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, Sachar EJ (1978) A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640–655

    Article  CAS  PubMed  Google Scholar 

  • Campbell M, Armenteros J, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997) Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Assoc Psychiatry 36:835–843

    Article  CAS  Google Scholar 

  • Chhangani B, Greydanus DE, Patel DR, Feucht C (2011) Pharmacology of sleep disorders in children and adolescents. Pediatr Clin N Am 58:273–291

    Article  Google Scholar 

  • Cortesi F, Giannotti F, Ivanenko A, Johnson K (2010) Sleep in children with autism spectrum disorder. Sleep Med 11:659–664

    Article  PubMed  Google Scholar 

  • Coury DL, Anagnostou E, Manning-Courtney P, Reynolds A, Cole L, McCoy R, Whitaker A, Perrin JM (2012) Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 130(Suppl 2):S69–76

    Google Scholar 

  • Dove D, Warrant Z, McPheeters ML, Taylor JL, Sathe NA, Veenstra-VanderWeele J (2012) Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics 130:717–726

    Article  PubMed Central  PubMed  Google Scholar 

  • Doyle CA, McDougle CJ (2012) Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci 14:263–279

    PubMed Central  PubMed  Google Scholar 

  • Eugene AL (2012) Children with hyperactivity & ASD research treatment study (CHARTS) consortium. Atomoxetine reduces ADHD symptoms in children with autism spectum disorder. Evid Based Ment Health 15:96–100

    Article  Google Scholar 

  • Farmer C, Thurm A, Grant P (2013) Pharmacotherapy for the core symptoms in autistic disorder: current status of research. Drugs 73:303–314

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Fatemi SH, Realmuto GM, Khan L, Thuras P (1998) Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 28:303–307

    Article  CAS  PubMed  Google Scholar 

  • Golubchik P, Sever J, Weizman A (2013) Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial. Clin Neuropharmacol 36:37–41

    Article  CAS  PubMed  Google Scholar 

  • Greydanus DE, Pratt HD, Sloane MA, Rappley MD (2003) Attention-deficit/hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum. Pediatr Clin North Am 50:1049–1092

    Article  PubMed  Google Scholar 

  • Greydanus DE, Pratt HD, Patel DR (2007) Attention deficit hyperactivity disorder across the lifespan. Dis Mon 53:65–132

    Article  Google Scholar 

  • Greydanus DE, Calles JL Jr, Patel DR (2008) Pediatric and adolescent psychopharmacology. Cambridge University Press, Cambridge, pp 199–222

    Book  Google Scholar 

  • Greydanus DE, Kaplan G, Antshel KM (2013) Attention deficit hyperactivity disorder: neuropsychologic and pharmacologic considerations. Int J Child Adolesc Health 6:22–30

    Google Scholar 

  • Guy W (1976) ECDEU assessment manual for psychopharmacology. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Washington, DC, pp 534–537

    Google Scholar 

  • Handen BL, Johnson CR, Lubetsky M (2000) Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245–255

    Article  CAS  PubMed  Google Scholar 

  • Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ (2013) Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. J Child Adolesc Psychopharmacol 23:194–199

    Article  CAS  PubMed  Google Scholar 

  • Healy A, Rush R, Ocain F (2011) Fragile X syndrome: an update on developing treatment modalities. ACS Chem Neurosci 17:402–410

    Article  Google Scholar 

  • Hosenbocus S, Chahai R (2013) Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 22:166–171

    PubMed Central  PubMed  Google Scholar 

  • Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R (2005) A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582–589

    Article  CAS  PubMed  Google Scholar 

  • Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E (2006) Divalproex sodium vs placebo in the treatment of repetitive behaviors in autism spectrum disorder. Int J Neuropsychopharmacol 9:209–213

    Article  CAS  PubMed  Google Scholar 

  • Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, Feirsen N, Pepa L, Anagnostou E (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorder Neuropsychopharmacology 35:990–998

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Huerta M, Bishop Sl, Duncan A, Hus V, Lord C (2012) Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. Am J Psychiatry 169:1056–1064

    Article  PubMed  Google Scholar 

  • Ipser JC, Stein DJ, Hawkridge S, Hoppe L (2009) Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 8:CD005170

    Google Scholar 

  • Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL (1992) Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322–327

    Article  CAS  PubMed  Google Scholar 

  • Kaplan G (2012) Pharmacotherapy of adolescent ADHD. In: Greydanus DR, Patel DR, Omar HA, Feucht C, Merrick J (eds) Adolescent medicine: pharmacotherapeutics in general, mental, and sexual health. De Cruyter, Boston, pp 201–226.

    Google Scholar 

  • Kaplan G (2013) What is new in adolescent psychiatry? A literature review and clinical implications. Adolesc Med State Art Rev 24:29–42

    PubMed  Google Scholar 

  • Kaplan G, McCracken JT (2012) Psychopharmacology of autism spectrum disorders. Pediatr Clin N Am 59:175–187

    Article  Google Scholar 

  • King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L, STAART Psychopharmacology Network (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66:563–590

    Article  Google Scholar 

  • Kotagal S, Broomall E (2012) Sleep in children with autism spectrum disorder. Pediatr Neurol 47:242–251

    Article  PubMed  Google Scholar 

  • Malone RP, Delaney MA, Hyman SB, Cater JR (2007) Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 17:779–790

    Article  PubMed  Google Scholar 

  • Mandell D, Morales K, Marcus SC, Stahmer AC, Doshi J, Polsky DE (2008) Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders. Pediatrics 121:e441–448

    Article  PubMed Central  PubMed  Google Scholar 

  • Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110–1119

    Article  PubMed  Google Scholar 

  • Martin A, Koenig K, Scahill L, Bregman J (1999) Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99–107

    Article  CAS  PubMed  Google Scholar 

  • McCracken JT (2010) Disruptive behaviors. In: Hollander E, Kolevzon A, Coyle JT (eds) Autism spectrum disorders. American Psychiatric Publishing, Washington, DC, pp 159–167.

    Google Scholar 

  • McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, Research Units on Pediatric Psychopharmacology Autism Network (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314–321

    Article  CAS  PubMed  Google Scholar 

  • McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996) A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001–1008

    Article  CAS  PubMed  Google Scholar 

  • McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142–1148

    Article  PubMed  Google Scholar 

  • Miano S, Ferri R (2010) Epidemiology and management of insomnia in children with autistic spectrum disorders. Paediatr Drugs 12:78–84

    Article  Google Scholar 

  • Murray MJ (2010) Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders. Curr Psychiatry Rep 12:282–288

    Article  Google Scholar 

  • Nazeer A (2011) Psychopharmacology of autistic spectrum disorders in children and adolescents. Pediatr Clin No Am 58:85–97

    Article  Google Scholar 

  • Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533–1540

    Article  PubMed  Google Scholar 

  • Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL, Cook EH Jr (2005) An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 44:343–348

    Article  PubMed  Google Scholar 

  • Paavonen EJ, Vehkalahi K, Vanhala R (2008) Sleep in children with Asperger syndrome. J Autism Dev Disord 38:41–51

    Article  PubMed  Google Scholar 

  • Pardo CA, Buckley A, Thurm A, Lee LC, Azhagiri A, Neville DM, Swedo SE (2013) A pilot open-label trial of minocycline in patients with autism and regressive features. J Neurodev Disord 5:9

    Article  PubMed Central  PubMed  Google Scholar 

  • Parikh MS, Kolevzon A, Hollander E (2008) Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 18:157–178

    Article  PubMed  Google Scholar 

  • Paykina N, Greenhill L (2008) Attention deficit hyperactivity disorder. In: Findling RL (ed) Clinical manual of child and adolescent psychopharmacology. American Psychiatric Publishing, Washington, DC, pp 33–87

    Google Scholar 

  • Politte LC, McDougle CJ (2014) Aytpical antipschotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 231:1023–1036

    Article  CAS  Google Scholar 

  • Posey DJ, Stigler KA, Erickson CA, McDougle CJ (2008) Antipsychotics in the treatment of autism. J Clin Invest 118:6–14

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Potenza MN, Holmes JP, Kanes SJ, McDougle CJ (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37–44

    Article  CAS  PubMed  Google Scholar 

  • Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J, Greenhill L (1995) Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25:283–294

    Article  CAS  PubMed  Google Scholar 

  • Richdale A (1999) Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child Neurol 41:60–66

    Article  CAS  PubMed  Google Scholar 

  • Robinson SJ (2012) Childhood epilepsy and autism spectrum disorders: psychiatric problems, phenotypic expression, and anticonvulsants. Neuropsychol Rev 22:271–279

    Article  PubMed  Google Scholar 

  • Roke Y, Buitelaar JK, Boot AM, Tenback D, van Harten PN (2012) Risk of hyperprolactinemia and sexual side effects in males 10–20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 22:432–439

    Google Scholar 

  • Research Units on Pediatric Psychopharmacology Autism Network (RUPPa) (2005a) Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361–1369

    Article  Google Scholar 

  • Research Units on Pediatric Psychopharmacology Autism Network (RUPPb) (2005b) Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders wtih hyperactivity. Arch Gen Psychiatry 62:1266–1274

    Article  Google Scholar 

  • Rush J, Nirenmberg A (2009) Mood disorders: treatment of depression. In: Sadock B, Sadock V, Ruiz P (eds) Kaplan and Sadock’s comprehensive textbook of psychiatry. Lippincott Williams & Wilkins, Philadelphia, pp 1734–1742

    Google Scholar 

  • Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Posey D, Young C, Shah B, Ghuman J, Ritz L, Vitiello B (2006) A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:589–598

    Article  PubMed  Google Scholar 

  • Schubart JR, Camacho F, Leslie D (2013) Psychotropic medication trends among children and adolescents with autism spectrum disorder in the medicaid program. Autism 18:631–637

    Article  PubMed  Google Scholar 

  • Sharma A, Shaw S (2012) Efficacy of risperidone in managing maladaptive behaviors for children with autism spectrum disorder: a meta-analysis. J Ped Health Care 26:291–299

    Article  Google Scholar 

  • Siegel M (2012) Psychopharmacology of autism spectrum disorder: evidence and practice. Child Adolesc Psychiatr Clin N Am 21:957–973

    Article  PubMed  Google Scholar 

  • Silver WG, Rapin I (2012) Neurobiological basis of autism. Pediatr Clin N Am 59:45–61

    Article  Google Scholar 

  • Tachibana M, Kagitani-Shimono K, Mohri I, Yamamoto T, Sanefuji W, Nakamura A, Oishi M, Kimura T, Onaka T, Ozono K, Taniike M (2013) Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorder. J Child Adolesc Psychopharmacol 23:123–127

    Article  CAS  PubMed  Google Scholar 

  • Taurines R, Schwenck C, Westerwald E, Sachse M, Siniatchkin M, Freitag C (2012) ADHD and autism: differential diagnosis or overlapping traits? A selective review. Atten Defic Hyperact Disord 4:115–139

    Article  PubMed  Google Scholar 

  • Tchaconas A, Adesman A (2013) Autistic spectrum disorders: a pediatric overview and update. Curr Opin Pediatr 25:130–144

    Article  PubMed  Google Scholar 

  • Tuchman RF (2013) Deconstructing autism spectrum disorders: clinical perspective. Rev Neurol 56:S3–12

    PubMed  Google Scholar 

  • Tordjman S, Najjar I, Bellissant E, Anderson GM, Barburoth M, Cohen D, Jaafari N, Schischmanoff O, Fagard R, Lagdas E, Kermarrec S, Ribardiere S, Botbol M, Fougerou C, Bronsard G, Vernay-Leconte J (2013) Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 14:20508–20542

    Article  PubMed Central  PubMed  Google Scholar 

  • Weblink #1 (2012) http://www.forbes.com/sites/emilywillingham/2012/10/11/new-dsm-5-criteria-for-autism-who-will-be-left-behind/

  • Weblink #2 http://www.nytimes.com/2012/01/20/health/research/new-Autism-definition-would-exclude-many-studysuggests.html?_pagewanted=all&module=Search&mabReward=-relbias%3Ar

  • Weblink #3 http://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia

  • Weblink #4 (2012) http://www.clinicaltrials.gov/ct2/show/NCT01725152?term=ganaxolone&rank=3

  • Williams K, Wheeler DM, Silove N, Hazell P (2013) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 8:CD004677

    PubMed  Google Scholar 

  • Young D, Nagarajan L, de Klerk N (2007) Sleep problems in Rett syndrome. Brain Dev 29:609–616

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric & Adolescent Medicine, Western Michigan University School of Medicine, 1000 Oakland Drive, D48G, 49008-1284, Kalamazoo, MI, USA

    Prof. Donald E. Greydanus MD & Prof. Dilip R. Patel MD, MBA

  2. Rutgers New Jersey Medical School, 535 Morris Avenue, 07081, Springfield, NJ, USA

    Asso. Prof. Gabriel Kaplan MD

Authors
  1. Prof. Donald E. Greydanus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asso. Prof. Gabriel Kaplan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dilip R. Patel MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald E. Greydanus MD .

Editor information

Editors and Affiliations

  1. Neuroscience and Pharmacology MMC 392, University of Minnesota Medical School, Minneapolis, Minnesota, USA

    S. Hossein Fatemi

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Greydanus, D., Kaplan, G., Patel, D. (2015). Pharmacology of Autism Spectrum Disorder. In: Fatemi, S. (eds) The Molecular Basis of Autism. Contemporary Clinical Neuroscience. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2190-4_9

Download citation

Publish with us

Policies and ethics

Search

Navigation